alexa Targeting lymphocyte activation to treat rheumatoid arthritis.


Journal of Pain Management & Medicine

Author(s): Falgarone G, Semerano L, Rull S, Boissier MC, Falgarone G, Semerano L, Rull S, Boissier MC

Abstract Share this page

Abstract The introduction of targeted treatments has radically changed the management of patients with rheumatoid arthritis (RA). Abatacept is among these new treatments emerging from recent insights into joint immunopathology. Abatacept blocks the interaction between antigen-presenting cells and T-cells, thereby diminishing T-cell activation and possibly improving overall cell regulation. In RA patients, abatacept is effective in decreasing the arthritis, pain, disability, fatigue, and radiological joint damage. Abatacept provides lasting remissions or low levels of disease activity and therefore constitutes a valuable addition to the current therapeutic armamentarium for RA, which is hoped to make a full remission an attainable goal in the overall population of RA patients. This article was published in Joint Bone Spine and referenced in Journal of Pain Management & Medicine

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • 4th International Conference and Exhibition on Pain Medicine
    August 03-04, 2017 San Francisco USA
  • 5th International Conference and Exhibition on Pain Research and Management
    September 04-05, 2017 London UK

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version